42
Participants
Start Date
December 31, 2011
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
BMS-982470 (recombinant interleukin-21)
Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
BMS-982470 (recombinant interleukin-21)
Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
BMS-982470 (recombinant interleukin-21)
Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
BMS-982470 (recombinant interleukin-21)
Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
Ipilimumab
Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
Ipilimumab
Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
Ipilimumab
Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa
University Of Louisville Medical Center, Inc., Dba, Louisville
Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis
Md Anderson Can Cnt, Houston
Oncology Research Associates, Pllc D/B/A, Scottsdale
Ucla Hematology/Oncology., Los Angeles
Portland Providence Medical Center, Portland
Seattle Cancer Care Alliance, Seattle
Local Institution, San Juan
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY